Functional interactions between 5-HT 2A and presynaptic 5-HT 1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT)

British Journal of Pharmacology

Volumn 159, Issue 4, 2010, Pages 879-887

  Fox, Meredith A ^a   Stein, Alison R ^a   French, Helen T ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT 1A receptors; 5 HT transporter (SERT) knockout mice; 5 HT 2A receptors; 8 OH DPAT; DOI; Fluvoxamine; Head twitch response; L745870; MDL 11,939; Serotonin (5 HT); WAY 100635

Indexed keywords

GLEMANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEAD TWITCH; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN; GENE DOSAGE; HEAD MOVEMENTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRESYNAPTIC TERMINALS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, PRESYNAPTIC; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 77249140558     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00578.x     Document Type: Article

References (55)

1. Abbas A, Roth BL (2008). Arresting serotonin. Proc Natl Acad Sci U S A 105 : 831 832.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Andrews AM, Murphy DL (1993). Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2′-NH2-MPTP): a comparative study with 2′-CH3-MPTP and MPTP. J Neurochem 60 : 1167 1170.
4. Basselin M, Fox MA, Chang L, Bell JM, Greenstein D, Chen M et al. (2009). Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. Neuropsychopharmacology 34 : 1695 1709.
5. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A et al. (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 53 : 649 655.
6. Bjork L, Cornfield LJ, Nelson DL, Hillver SE, Anden NE, Lewander T et al. (1991). Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther 258 : 58 65.
7. Bouali S, Evrard A, Chastanet M, Lesch KP, Hamon M, Adrien J (2003). Sex hormone-dependent desensitization of 5-HT1A autoreceptors in knockout mice deficient in the 5-HT transporter. Eur J Neurosci 18 : 2203 2212.
8. Cesana R, Ceci A, Ciprandi C, Borsini F (1993). Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 45 : 473 475.
9. Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006). WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) 188 : 244 251.
10. Darmani NA (1998). The silent and selective 5-HT1A antagonist, WAY 100635, produces via an indirect mechanism, a 5-HT2A receptor-mediated behaviour in mice during the day but not at night. Short communication. J Neural Transm 105 : 635 643.
11. Darmani NA, Martin BR, Pandey U, Glennon RA (1990). Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36 : 901 906.
12. Darmani NA, Reeves SL (1996). The mechanism by which the selective 5-HT1A receptor antagonist S-(-) UH 301 produces head-twitches in mice. Pharmacol Biochem Behav 55 : 1 10.
13. Daws LC, Montanez S, Munn JL, Owens WA, Baganz NL, Boyce-Rustay JM et al. (2006). Ethanol inhibits clearance of brain serotonin by a serotonin transporter-independent mechanism. J Neurosci 26 : 6431 6438.
14. Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, Lesch KP et al. (2000). Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 12 : 2299 2310.
15. Fox MA, Jensen C, Gallagher P, Murphy D (2007a). Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 53 : 643 656.
16. Fox MA, Andrews AM, Wendland JR, Lesch KP, Holmes A, Murphy DL (2007b). A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl) 195 : 147 166.
17. 2A receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology (Berl). doi:10.1007/s00213-009- 1694-1.
18. Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ et al. (2008). Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology (Berl) 201 : 203 218.
19. Fox MA, Jensen CL, Murphy DL (2009). Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol 12 : 1055 1065.
20. Gartside SE, Umbers V, Hajos M, Sharp T (1995). Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115 : 1064 1070.
21. Gobbi G, Murphy DL, Lesch K, Blier P (2001). Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 296 : 987 995.
22. Gobert A, Dekeyne A, Millan MJ (2000). The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39 : 1608 1616.
23. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R et al. (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53 : 439 452.
24. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M et al. (2003). Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23 : 8836 8843.
25. Gundlah C, Hjorth S, Auerbach SB (1997). Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology 36 : 475 482.
26. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D et al. (2000). Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 130 : 539 548.
27. Hjorth S (1993). Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 60 : 776 779.
28. Hjorth S, Westlin D, Bengtsson HJ (1997). WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36 : 461 465.
29. Holmes A, Li Q, Murphy DL, Gold E, Crawley JN (2003a). Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2 : 365 380.
30. Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL (2003b). Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28 : 2077 2088.
31. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46 : 157 203.
32. Iasevoli F, Tomasetti C, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A (2009). Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Prog Neuropsychopharmacol Biol Psychiatry 33 : 813 821.
33. Jennings KA, Sheward WJ, Harmar AJ, Sharp T (2008). Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology 54 : 776 783.
34. Kim DK, Tolliver TJ, Huang SJ, Martin BJ, Andrews AM, Wichems C et al. (2005). Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 49 : 798 810.
35. Kobayashi T, Hayashi E, Shimamura M, Kinoshita M, Murphy NP (2008). Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 197 : 567 580.
36. Krall CM, Richards JB, Rabin RA, Winter JC (2008). Marked decrease of LSD-induced stimulus control in serotonin transporter knockout mice. Pharmacol Biochem Behav 88 : 349 357.
37. Li Q, Wichems C, Heils A, Lesch KP, Murphy DL (2000). Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci 20 : 7888 7895.
38. Li Q, Wichems C, Heils A, Van De Kar LD, Lesch KP, Murphy DL (1999). Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther 291 : 999 1007.
39. Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL (2003). Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 84 : 1256 1265.
40. Marona-Lewicka D, Nichols DE (2009). WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation. Behav Pharmacol 20 : 114 118.
41. Martel JC, Leduc N, Ormiere AM, Faucillon V, Danty N, Culie C et al. (2007). WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur J Pharmacol 574 : 15 19.
42. Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004). Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140 : 169 181.
43. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (2006). 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 49 : 5794 5803.
44. Milstein J, Dalley J, Robbins T (2010). Methylphenidate-induced impulsivity: pharmacological antagonism by {beta}-adrenoreceptor blockade. J Psychopharmacol (in press).
45. Montanez S, Owens WA, Gould GG, Murphy DL, Daws LC (2003). Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J Neurochem 86 : 210 219.
46. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK et al. (2007). Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321 : 1054 1061.
47. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007). Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 192 : 357 371.
48. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006). Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31 : 265 277.
49. Qu Y, Villacreses N, Murphy DL, Rapoport SI (2005). 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl) 180 : 12 20.
50. Rioux A, Fabre V, Lesch KP, Moessner R, Murphy DL, Lanfumey L et al. (1999). Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett 262 : 113 116.
51. Romero L, Hervas I, Artigas F (1996). The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 219 : 123 126.
52. Schmid CL, Raehal KM, Bohn LM (2008). Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105 : 1079 1084.
53. Sharp T, Boothman L, Raley J, Queree P (2007). Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 28 : 629 636.
54. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H et al. (2004). Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29 : 1790 1799.
55. Willins DL, Meltzer HY (1997). Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282 : 699 706.